References
- Fisher JP, Heuijerjans J, Yan M, Gustafsson K, Anderson J. γδ T cells for cancer immunotherapy: a systematic review of clinical trials. Oncoimmunology 2014; 3:e27572; PMID:24734216; http://dx.doi.org/10.4161/onci.27572
- Himoudi N, Morgenstern DA, Yan M, Vernay B, Saraiva L, Wu Y, Cohen CJ, Gustafsson K, Anderson J. Human γδT lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol 2012; 188:1708-16; PMID:22250090; http://dx.doi.org/10.4049/jimmunol.1102654
- Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T cells. Science 2005; 309:264-8; PMID:15933162; http://dx.doi.org/10.1126/science.1110267
- Hviid L, Akanmori BD, Loizon S, Kurtzhals JA, Ricke CH, Lim A, Koram KA, Nkrumah FK, Mercereau-Puijalon O, Behr C. High frequency of circulating gamma delta T cells with dominance of the v(delta)1 subset in a healthy population. Int Immunol 2000; 12:797-805; PMID:10837407; http://dx.doi.org/10.1093/intimm/12.6.797
- Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE et al. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther 2013; 21:638-47; PMID:23295945; http://dx.doi.org/10.1038/mt.2012.267
- Deniger DC, Maiti S, Mi T, Switzer K, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls H et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res 2014; 20(20):5708-19; PMID:24833662; http://dx.doi.org/10.1158/1078-0432.CCR-13-3451
- Fisher J, Yan M, Heuijerjans J, Carter L, Abolhassani A, Frosch J, Wallace R, Flutter B, Hubank M, Klein N et al. Neuroblastoma killing properties of V-delta 2 and V-delta2 negative gamma delta T cells following expansion by artificial antigen presenting cells. Clin Cancer Res 2014; 20(22):5720-32.
- Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
- Fournié J-J, Sicard H, Poupot M, Bezombes C, Blanc A, Romagné F, Ysebaert L, Laurent G. What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol 2013; 10(1):35-41.
- Kabelitz D, Pechhold K, Bender A, Wesselborg S, Wesch D, Friese K, Janssen O. Activation and activation-driven death of human gamma/delta T cells. Immunol Rev 1991; 120:71-88; PMID:1677929; http://dx.doi.org/10.1111/j.1600-065X.1991.tb00588.x